ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2170

Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)
Abstract Number: 0703

Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Abstract Number: 0376

Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Abstract Number: 1549

Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Abstract Number: 1536

Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
Abstract Number: 2053

Presence of ANA to Development of Rheumatic Diseases
Abstract Number: 0552

Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
Abstract Number: 2205

Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Abstract Number: 2554

Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska
Abstract Number: 0619

Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
Abstract Number: 1156

Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 2461

Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy
Abstract Number: 2520

Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Abstract Number: 1200

Prevalence and Joint Involvement Patterns of Erosive and Non-erosive Hand Osteoarthritis in the General Population in China
Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].